BioInfect 2014 to Gather Life Science Professionals and Set the Global Antimicrobial Agenda
Bionow will be hosting the 2014 BioInfect Conference. A major one-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, will take place at the Alderley Park Conference Centre, Cheshire on the 4 November 2014. The conference will again convene scientists, policy makers and government officials from across the world to drive forward and establish the global anti-microbial agenda.
The three main sessions that will be presented at the conference are “Progress: National and International Perspectives”, “Animal Health — the issues” and “Commercial Models.” In addition, there will be company technology showcases presenting leading innovation and development in this area. These include North West based Redx Anti-Infectives and Blueberry Therapeutics, QuantuMDx who are based in Newcastle and Discuva who are based in Cambridge.
Dr Geoff Davison, CEO of Bionow, commented: “To tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way to ensure that we have a health care system that can sustainably control and treat infections. BioInfect is a wonderful opportunity to bring together professionals from the life sciences industry, government and policy making bodies and explore the areas which can truly address this problem for mankind.”
BioInfect 2014 follows on from a very successful conference last year where Professor Dame Sally Davies, Chief Medical Officer, noted that "the golden age" of effective antibiotics has come to an end as no new class of drugs has been developing since 1987. She warned of the danger of going back to a pre-antibiotic era, where a simple infection could be a death sentence - a warning echoed by other speakers from around the globe. This year the Deputy Chief Medical Officer, Professor John Watson will inform delegates of the progress which the UK is making in the fight against this deadly threat.
BioInfect 2014, is hosted by Bionow and Redx Pharma, supported by AstraZeneca and sponsored by HGF Ltd, Boyd Consultants, Shore Capital and DWF LLP.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...